Your browser doesn't support javascript.
loading
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Rejeski, Kai; Blumenberg, Viktoria; Iacoboni, Gloria; Lopez-Corral, Lucia; Kharboutli, Soraya; Hernani, Rafael; Petrera, Agnese; Müller, Niklas; Hildebrand, Friederike; Frölich, Lisa; Karschnia, Philipp; Schmidt, Christian; Cordas Dos Santos, David M; Piñana, José Luis; Müller, Fabian; Martin, Ana Africa; Dreyling, Martin; von Bergwelt-Baildon, Michael; Barba, Pere; Subklewe, Marion; Bücklein, Veit L.
Afiliação
  • Rejeski K; Department of Medicine III - Hematology/Oncology, University Hospital, LMU Munich, Germany.
  • Blumenberg V; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Iacoboni G; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
  • Lopez-Corral L; Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany.
  • Kharboutli S; Department of Medicine III - Hematology/Oncology, University Hospital, LMU Munich, Germany.
  • Hernani R; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
  • Petrera A; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
  • Müller N; Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany.
  • Hildebrand F; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Barcelona, Spain.
  • Frölich L; Department of Medicine, Universitat Autònoma of Barcelona (UAB), Bellaterra, Spain.
  • Karschnia P; Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.
  • Schmidt C; Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.
  • Cordas Dos Santos DM; Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany.
  • Piñana JL; Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Germany.
  • Müller F; Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain.
  • Martin AA; Metabolomics and Proteomics Core Facility, Helmholtz Zentrum Munich - German Research Center for Environmental Health, Munich, Germany.
  • Dreyling M; Department of Medicine III - Hematology/Oncology, University Hospital, LMU Munich, Germany.
  • von Bergwelt-Baildon M; Department of Medicine III - Hematology/Oncology, University Hospital, LMU Munich, Germany.
  • Barba P; Department of Medicine III - Hematology/Oncology, University Hospital, LMU Munich, Germany.
  • Subklewe M; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany.
  • Bücklein VL; Department of Neurosurgery, University Hospital, LMU Munich, Germany.
Hemasphere ; 7(4): e858, 2023 Apr.
Article em En | MEDLINE | ID: mdl-37038465
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hemasphere Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hemasphere Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Estados Unidos